Novo Nordisk increased operating profit by 34% in the first nine months of 2012 (31 October 2012)

Novo Nordisk increased operating profit by 34% in the first nine months of 2012 (31 October 2012)

Sales grew 18% driven by Victoza®, NovoRapid® and Levemir®

    Sales grew 18% to 57.1 billion in Danish kroner and by 11% in local currencies. - Sales of modern insulins increased by 21% (14% in local currencies).- Sales of Victoza® increased by 74% (64% in local currencies).- Sales in North America increased by 30% (19% in local currencies).- Sales in International Operations increased by 19% (16% in local currencies).

    Reported gross margin improved by 1.5 percentage points to 81.9%.

    Reported operating profit increased by 34% to DKK 21,902 million. Measured in local currencies, operating profit increased by 21%.

    Net profit increased by 26% to DKK 15,677 million. Earnings per share (diluted) increased by 31% to DKK 28.32.

    The regulatory process for the new generation insulins, with the intended brand names Tresiba® and Ryzodeg®, continues to progress in the major markets. In Japan, Tresiba® has now been approved and in Europe, CHMP has issued positive opinions for Tresiba® and Ryzodeg®. In the US, the FDA has disclosed that the Advisory Committee meeting to discuss the new drug applications on 8 November 2012 will focus on the benefits associated with a lower risk of hypoglycaemia and the cardiovascular risk profiles of the two products.

    For 2012, sales growth measured in local currencies is now expected to be 10-12% (previously 9-12%), and operating profit growth measured in local currencies is now expected to be 16-18% (previously around 15%).

    The preliminary outlook for 2013 indicates high single-digit sales and operating profit growth, both measured in local currencies. The outlook includes an expected positive sales contribution from Tresiba®, primarily in the US, EU and Japan, countered by an impact from the challenging operating environment in major markets. In addition, the outlook for operating profit reflects significant costs related to the expected launch of Tresiba®.

Lars Rebien Sørensen, president and CEO: "Continued strong sales of our modern insulins and Victoza® have led to a robust financial performance in the first nine months of 2012. The approval of Tresiba® in Japan and the positive CHMP opinions in Europe for Tresiba® and Ryzodeg® constitute two significant milestones in the process of bringing this new generation of insulin to the market."
Contacts for further information
Mike Rulis  +45 4442 3573  [email protected]
Ken Inchausti (US)  +1 609 514 8316  [email protected]
Kasper Roseeuw Poulsen  +45 4442 4303  [email protected]
Frank Daniel Mersebach  +45 4442 0604  [email protected]
Lars Borup Jacobsen  +45 3075 3479  [email protected]
Jannick Lindegaard (US)  +1 609 786 4575  [email protected]

Company announcement No 70 / 2012

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.